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Abstract
Background Many melanoma observational studies have been carried out across different countries and geographic
areas using heterogeneous assessments of epidemiologic risk factors and clinical variables.
Aim To develop a consensus questionnaire to standardize epidemiologic and clinical data collection for melanoma risk
assessment.
Methods We used a stepwise strategy that included: compilation of variables from case–control datasets collected at
various centres of the MelaNostrum Consortium; integration of variables from published case–control studies; consen-
sus discussion of the collected items by MelaNostrum members; revision by independent experts; addition of online
tools and image-based charts; questionnaire testing across centres and generation of a final draft.
Results We developed a core consensus questionnaire (MelanoQ) that includes four separate sections: A. general and
demographic data; B. phenotypic and ultraviolet radiation exposure risk factors and lifestyle habits; C. clinical examination,
medical and family history; and D. diagnostic data on melanoma (cases only). Accompanying online tools, informative
tables, and image-based charts aid standardization. Different subsections of the questionnaire are designed for self-
administration, patient interviews performed by a physician or study nurse, and data collection frommedical records.
Conclusions The MelanoQ questionnaire is a useful tool for the collection and standardization of epidemiologic and
clinical data across different studies, centres, cultures and languages. This will expedite ongoing efforts to compile high-
quality data for pooled analyses or meta-analyses and offer a solid base for the design of clinical, epidemiologic and
translational studies on melanoma.
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Introduction
The incidence of cutaneous melanoma (CM) has steadily and
significantly increased in populations of European descent in
recent years,1 including the Mediterranean populations.2–4 CM
is responsible for the largest proportion (60–80%) of skin can-
cer-related deaths.5 In 2012, more than 232 000 people world-
wide were diagnosed with CM and more than 55 400
succumbed to the disease.5,6 Data from population-based Euro-
pean registries have shown an increased incidence of in situ and
invasive melanoma but a stable mortality rate in Italy and Spain
between 1995 and 2012.7 Melanoma risk factors include ultravi-
olet (UV) radiation exposure, positive family history for mela-
noma, phenotypic traits with a strong genetic component such
as red or blonde hair, light-coloured eyes, and fair skin com-
plexion, and an increased number of common and atypical
melanocytic nevi. Even though the advent of targeted therapies
and immune checkpoint inhibitors has improved melanoma
prognosis in a subgroup of patients, the mortality risk and the
socio-economic burden associated with advanced disease
emphasize the importance of prevention strategies in high-risk
individuals and of screening programs for early detection.
Numerous case–control studies have been carried out focusing
on the environmental and phenotypical risk factors of CM.8–16
The variables assessed were often heterogeneous, and this has
limited the possibility of pooled analyses. Tools for standardized
data recording are therefore needed to design prospective studies
and to guide retrieval of previously collected data across various
centres. Earlier questionnaires or surveys in melanoma studies
focused only on few variables or lacked high test–retest reliabil-
ity.17–21 We sought to generate a comprehensive tool that would
allow us to pool data from studies on CM carried out by the
MelaNostrum Consortium as well as by other centres.
MelaNostrum is an international Consortium of researchers
and clinicians involved in melanoma research in Mediterranean
(i.e. Southern European) populations, which have been, so far,
under-represented in studies of CM. Formally established in
2017, MelaNostrum comprises experts in various disciplines,
including epidemiologists, dermatologists, medical oncologists,
pathologists, molecular biologists, geneticists and statisticians.
The primary goals of MelaNostrum were as follows: (i) to iden-
tify genetic, environmental and phenotypic features associated
with melanoma risk; (ii) to investigate disease development and
clinical outcomes using molecular classification of melanoma
and of melanoma precursors and (iii) to study the role of genet-
ics and immunity in melanoma progression and response to
treatment. Currently, MelaNostrum collects and analyzes data
and biological samples from 12 centres across Greece, Italy and
Spain. A complete list of current MelaNostrum centres and
members is provided as Table S1.
Given the heterogeneous recording of variables across mela-
noma studies, the MelaNostrum investigators were confronted
with the difficult task of harmonizing epidemiologic and clinical
information from each centre to perform association studies.
The present work reports on the stepwise strategy employed to
†Contributed equally to this study and share first authorship.
A complete list of members of the MelaNostrum Consortium is provided in the
Table S1.
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develop a data collection tool (hereafter named as MelanoQ)
that could be used as a full or itemized template for the stan-
dardization of retrospective data from case–control and other
epidemiology studies or in prospective studies aimed at the
investigation of genetic, lifestyle, epidemiologic and clinical fac-
tors associated with melanoma.
Material and methods
Development of the questionnaire
The questionnaire was developed in 7 steps as outlined in Fig. 1.
Step 1: compilation of variables from case–control datasets
collected by the MelaNostrum centres. Step 2: distribution of the
variable list to MelaNostrum members, initial evaluation of
differences and similarities across centres and categorization of
the items in sections. This step also included enrichment of the
variables based on published case–control studies. Step 3: two
face-to-face meetings of the MelaNostrum clinical core of inves-
tigators, during which each variable in the list was discussed.
The first meeting also involved physical examination of patients
to achieve consensus on criteria for nevus count and (other) pig-
mented skin lesion diagnosis. As a result, a draft of the MelanoQ
was generated (Barcelona, Spain) and subsequently improved
(Athens, Greece). Step 4: review of the draft questionnaire by an
independent expert panel (MT, DW, VB) and implementation
of the suggested modifications. Step 5: addition of (i) online
tools to ease recording of residency and occupations, (ii) tables
with lists of ethnicities, outdoor occupations and recreational
activities, and (iii) image-based charts for data standardization
pertaining to eye and hair colour, tanning ability, freckles and
nevi number. Step 6: questionnaire testing across centres, using
different languages and recording the time required for comple-
tion. Step 7: establishment of the final draft after consensus dis-
cussion through email exchange by the MelaNostrum team.
Results
MelanoQ is organized in 4 main sections (A-D) and includes a
total number of 64 items related to: general and demographic
information (section A); phenotypic, UV exposure risk factors
and lifestyle habits (section B); clinical examination, medical his-
tory and family history (section C); tumour characteristics,
including histology, staging and molecular profile (section D).
Only sections A, B and C are included in the MelanoQ for con-
trols. In each section, the items are formulated as closed-ended
questions with only few exceptions. Different subsections are
designed for self-administration, patient/control interviews per-
formed by a physician or study nurse, and data collection from
medical records. The questionnaire is briefly outlined in Table 1,
while it is provided in full as Table S2.
Section A should be filled in by the physician or study nurse
(subsection I) and by the study participant (subsection II). In
subsection I, the date of questionnaire administration and
Collection of variables from case/control datasets
of the MelaNostrum clinical centers
Step 1.
Distribution of preliminary list of variables to MelaNostrum members for 
evaluation, categorization, and enrichment by literature review
Step 2.
Face-to-face meetings* to discuss each variable and 
development of a draft questionnaire
Step 3. 
Assessment of the questionnaire by 
an independent expert panel**
Step 4.
Addition of online tools, tables, and image-based chartsStep 5.
Questionnaire testing across centersStep 6.
Establishment of the final consensus questionnaireStep 7.
Figure 1 Stepwise strategy used to develop the MelanoQ. *one meeting including patient examination to define criteria for pigmented
lesion assessment and nevus count. **The expert panel consisted of M. Tucker (USA), V. Bataille (UK) and D. Whiteman (Australia).
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phenotyping is annotated and the date(s) of the updated pheno-
typing can also be recorded if additional patient interviewing or
clinical evaluation is performed during follow-up. Subsection II
includes questions about age, sex, weight and height, ethnicity,
residency, education and occupation. The question about the
place of residence is open-ended to capture all possible changes
(and duration thereof). To facilitate categorization, geocoding is
advisable. The question regarding history of occupation is also
designed as open-ended and could also be supported by online
tools or flash cards. The question about education has been har-
monized to take into account country-specific differences. For
this purpose, age categories defining educational levels have
been set broadly to enable collection of the relevant data across
different cohorts.
Section B is completed by the study subject. Its subsection I
pertains to epidemiologic and clinical risk factors including skin
type, eye colour, hair colour, freckling and nevi in childhood/
adolescence. To facilitate consistency in data reporting, the ques-
tions regarding the skin type are formulated to combine the sub-
ject’s skin response to sun exposure with his/her ability to tan
(Figure S1). The term ‘skin colour’ is not included in MelanoQ
to avoid subjective assessment. Information on eye and hair col-
our has been merged into fewer categories (light: blue/green/
grey, medium: light brown/hazel and dark: dark brown/black,
for eye colour; and red, blond, light brown, dark brown and
black, for hair colour) to facilitate statistical analyses. Definition
of freckles and solar lentigines is included to ensure proper iden-
tification of these lesions. Charts with images of eye and hair col-
our (Figures S2 and S3, respectively), as well as freckle and nevi
density (Figures S4 and S5, respectively) have been included to
standardize categorization and recording. Section B also includes
questions on occupational and recreational sun exposure, use of
artificial tanning, sunburns and the use of sun protection meth-
ods (subsection II). Information on sun exposure and related
behaviours also includes data on intermittent sun exposure
(during childhood, adolescence and adulthood, as well as during
a 10-year period prior to melanoma diagnosis). The number and
age of occurrence (<18 years or ≥18 years) of severe (grade 2)
sunburns are also recorded, as is their site with respect to mela-
noma (where applicable). The use of sunscreen is categorized as
never, <50% or >50% of the time during sun exposure, always,
or not known, over four periods of life. Additional questions
focus on lifestyle habits, specifically, vitamin intake and smoking
history (subsection III).
Section C includes clinical examination, detailed medical his-
tory and family history of melanoma/other cancers for both
cases and controls. This section is designed to be completed by a
health care professional. The clinical examination part aims at
recording the presence of multiple and/or clinically atypical mel-
anocytic nevi, congenital melanocytic nevi, blue nevi, actinic
keratoses and keratinocyte skin cancer KSC (basal cell carcinoma
and squamous cell carcinoma) (subsection I). Nevi >2 mm in
size are recorded as a continuous variable by site and by lateral-
ity. Clinically, atypical nevi are defined as having a macular com-
ponent in at least one part of the lesion (mandatory), and
having at least 3 of the following criteria: >5 mm diameter, col-
our variegation, irregular borders or erythema.22,23 Congenital
nevi classified as medium-sized (>1.5–19.9 cm), large (≥20 cm),
or giant (≥40 cm) are recorded as present or absent and their
site is noted. The presence of actinic keratoses is also recorded
Table 1 Design and variables of MelanoQ.
Section Completed by Variables Items
SECTION A (case/control)
General Physician/study nurse Subject ID, date and update of questionnaire, sporadic/familial case 1–5
Demographic Self-administered Sex, age, weight, height, ethnicity, residency,
education, and occupation
6–13
SECTION B (case/control)
Phenotype Self-administered Skin type, eye/hair colour, freckles, nevi in childhood 1–5
History of sun and UVR exposure Self-administered Sun exposure and related habits, sunburns, lamps 6–14
Lifestyle habits Self-administered Vitamins, smoking 15–18
Section B Completion evaluation questions Self-administered Questionnaire evaluation 19–20
SECTION C (case/control)
Clinical examination Physician/study nurse SOLAR lentigines, nevi, actinic keratosis 1–8
Medical history/medications Physician/study nurse Non-cancer diagnoses, treatments, pregnancies, other cancers 9–13
Family history Physician/study nurse Melanoma and other cancers among relatives, genetic test 14–16
Section C Completion evaluation questions Physician/study nurse Questionnaire evaluation 17–18
SECTION D (case)
Melanoma characteristics
(for each melanoma diagnosis)
Physician/study nurse Clinical presentation, number of melanomas,
date of diagnosis, site, histological type and
features, SLN*, AJCC stage, mutation status
1–13
*Sentinel Lymph Node Biopsy.
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specifying site and distribution and recommending the use of
recently described scoring systems such as the AKASI or AK-FAS
scores.24,25 Information about the presence of KSC at the time of
physical examination (subsection I) or of any history of previous
KSC (subsection II) is also recorded, in the latter case with
details on tumour type, number of tumours and time of appear-
ance with respect to melanoma diagnosis. Additional questions
in this section focus on medical history, reproductive history
and medications (subsection II). Finally, subsection III collects
information about family history of melanoma and other can-
cers. A positive family history of melanoma is considered rele-
vant in the presence of ≥2 first- to third-degree relatives affected
by in situ or invasive melanoma. This definition takes into
account the generally lower incidence of melanoma in the
Mediterranean basin compared to other geographical regions,
and the specific features of the Mediterranean populations.26 If
possible, a family pedigree for each subject reporting a positive
family history of melanoma should be added to the collected
information.
Section D is the diagnostic section of the questionnaire
designed for patients with a confirmed diagnosis of melanoma.
It should be completed by a health care professional and aims to
collect data on clinical presentation, including site of primary
melanoma, Breslow thickness (and other major histopathologic
features), American Joint Committee on Cancer (AJCC) stage,
date of diagnosis and somatic mutational data (if available)
(subsection I). All thirteen items should be recorded separately
for each melanoma if the patient received multiple melanoma
diagnoses. Notably, MelanoQ includes twelve items, which are
marked as optional, that is to be collected only for the purpose
of more detailed analyses.
We have tested MelanoQ in a total of 62 patients at five Mela-
Nostrum centres in Italy, Spain, Greece. The time required for
completion ranged from 22 to 60 minutes (average 40 min).
Although the completion time of the medical sections (C and D)
was similar across physicians and centres (15–20 min), the self-
administered part (Section B) was more variable in duration
(12–30 min). In particular, questions 6–9 and 11 in subsection
II (Section B) required a longer time especially in more senior
patients/controls or patients with lower educational background.
When we added the assistance of an interviewer for these people,
the completion time decreased and the quality of the informa-
tion increased substantially. We thus have added a separate eval-
uation section (questions #19, 20 in Section B and questions
#17, 18 in Section C) that enables to score the degree of difficulty
in responding to the self-administered questions in section B as
well as to the phenotypical/clinical information in Section C by
the physician/nurse.
Discussion
Upon establishment of the MelaNostrum Consortium, one of
the major issues that members had to deal with (and solve) was
the incomplete or heterogeneous recording of the information
on melanoma patients’ specific risk factors, especially skin pho-
totype, sun exposure patterns and nevus assessment, collected
at each participating centre. We report herein on the develop-
ment of a standardized tool that expedites collection of epi-
demiologic and clinical data on CM from diverse case–control
datasets to allow association analyses across different centres.
MelanoQ also provides a template for data compilation for
prospective studies, clinical research projects or trials. Even
though it has been designed more as a research tool for epi-
demiologic studies and may not be suitable for completion in
the context of the rapid pace of daily clinical practice, it may
also serve as database for collection of pertinent clinico-patho-
logical information on newly diagnosed patients in melanoma
centres.
Previous questionnaires for melanoma studies include the
Q-skin,27 the Sun Exposure Behaviour Inventory (SEBI),17 and
the Sun Exposure and Protection Index (SEPI),18 among
others.19–21 The Q-skin questionnaire is considered one of the
most complete tools. However, its test–retest reliability for the
measurement of phenotypic characteristics, sun exposure and
nevus-related variables was not high.27 Similarly, the repeatabil-
ity of the SEBI instrument, which was limited in scope, since it
was designed to assess current and prior sun exposure, was
found to be only satisfactory.17 MelanoQ has the advantage of
allowing collection of data on individual risk assessment for epi-
demiologic purposes, but it can also be used as an entry tool by
clinical centres managing melanoma patients. At the same
time, although certain items in MelanoQ should be collected
by clinicians or specialized personnel, several parts can be
self-administered.
In designing this data collection tool, we first identified the
most relevant questions to be used for investigating disease aeti-
ology and progression. We also strove to clearly formulate sim-
ple questions for the lay public and precoded the responses for
statistical analyses. In order to facilitate data collection, we
added charts for eye colour, hair colour, freckling and nevus
density, lists of ethnicities, examples of outdoor occupations and
recreational activities and online tools for residency and occupa-
tion recording. Finally, we added an evaluation section to iden-
tify the most challenging self-administered questions that may
need follow-up by the investigators.
An important part of MelanoQ relates to the collection of
information on pigmentation characteristics. Fair skin type
(Fitzpatrick I or ΙΙ),28 red or blond hair and the presence of
freckles have all been associated with a higher risk of
melanoma.2915,16,30–34 Eye colour has also shown an association
with melanoma risk in numerous studies.15,16,35–38 In MelanoQ,
we have reproduced the categorization of pigmentary features
that has been used for melanoma studies, with a larger spectrum
of phototypes for subjects with relatively dark complexion, like
those in the Mediterranean population.
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The importance of recreational/intermittent sun exposure for
melanoma risk has been well documented, while the role of
occupational/continuous sun exposure remains unclear.13,39 A
standardized way of recording these two types of exposure by
self-administered questionnaires has been proposed, which aims
at capturing the amount of exposure time during daylight hours
for both recreational and occupational activities.40 Previous
studies with existing standardized tools have shown reasonable
reproducibility although the validity of the responses is
unclear.41,42 The items specifically related to sun exposure in
MelanoQ have been designed as simple, closed-ended questions.
For instance, for intermittent sun exposure, a short description
is included (i.e. in spring and summer time) and the case/control
subject is requested to provide an answer for four predesignated
time periods (section B-II, question 8). We also included ques-
tions to record sunscreen use and sun protection methods over
time.43,44
The identification and recording of common melanocytic and
atypical nevi–two well-established risk factors associated with a
high risk of melanoma–proved to be one of the most difficult
tasks in the epidemiologic investigation of melanoma.12,45
Although the issues associated with the identification of melano-
cytic lesions were partially addressed by the implementation of
dermoscopy in the daily clinical practice, the need for a harmo-
nized way to record nevus counts still exists. Before deciding
how to collect nevi data, the MelaNostrum clinicians discussed
the diagnosis and measurement criteria, reviewed the abundant
literature on the topic12,22,23,45–47 and addressed the inter-obser-
ver differences in nevus count.48,49 The group also performed
joint patient examinations to reach a consensus on how to
report, easily and precisely, nevus counts and relevant risk fac-
tors. The questions in MelanoQ are in agreement with the Inter-
national Agency for Research on Cancer (IARC) protocol for the
identification and recording of nevi,47,50 which has been imple-
mented in previous studies.51–54 Items that can help one to col-
lect information on the presence of congenital nevi sized
>1.5 cm, and particularly those with diameter ≥20 cm or giant
nevi, which are considered at risk of malignant transformation,
have also been included in our tool.55–59
Section D of MelanoQ contains highly structured questions
regarding patient melanoma diagnosis, including anatomical site
of the lesion, tumour histopathologic features and tumour
mutational status information (if applicable). The completeness
of the clinical and histopathological data collected by the SEER
registries and their impact on the transition from the AJCC 6th
to the 7th edition with regards to stage distribution has been
previously assessed.60 It was reported that about 10% of cases
were coded as unknown for measured thickness, ulceration and
lymph node metastasis, suggesting the need for enhanced data
capture for staging purposes.60 We created a specific checklist
for melanoma diagnosis data collection to reduce the possibility
of incomplete data recording as a result of human error.
MelanoQ can be enriched with additional items to generate
hypothesis-driven questions and to include new information
that may prove to be associated with melanoma risk in the
future. Our tool may expedite ongoing efforts to compile high-
quality data for pooled analyses or meta-analyses and offer a
solid base for the design of clinical, epidemiologic and transla-
tional studies on melanoma. We have already tested MelanoQ
across different clinical centres, languages and cultures in
Greece, Italy and Spain and plan, as a future step, to verify its
validity and repeatability by applying it to other populations.
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